Showing results (21-30 of 77) with videos related to
Sort By:
Pageof 8
Ejhaem|January 28, 2025
Chronic Severe Neutropenia Associated With Intravenous Immunoglobulin for Multifocal Motor NeuropathyShannon Ugarte, Talia Gebhard, David R Cornblath, et al.Journal of the Peripheral Nervous System : JPNS|April 1, 2018
A randomised, multi-centre phase III study of 3 different doses of intravenous immunoglobulin 10% in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ProCID trial): Study design and protocolDavid R Cornblath, Hans-Peter Hartung, Hans D Katzberg, et al.Journal of the Peripheral Nervous System : JPNS|August 29, 2018
Second IVIg course in Guillain-Barré syndrome patients with poor prognosis (SID-GBS trial): Protocol for a double-blind randomized, placebo-controlled clinical trialChrista Walgaard, Bart C Jacobs, Hester F Lingsma, et al.The Lancet. Neurology|May 12, 2019
Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathyCarina Bunschoten, Bart C Jacobs, Peter Y K Van den Bergh, et al.Journal of Clinical Neuromuscular Disease|January 27, 2009
Peripheral nerve vasculitis presenting as complex regional pain syndromeSindhu Ramchandren, Vinay Chaudhry, Ahmet Hoke, et al.Vaccine|October 18, 2011
Guillain-Barré Syndrome in India: population-based validation of the Brighton criteriaFarrah J Mateen, David R Cornblath, Hamid Jafari, et al.Brain : a Journal of Neurology|January 17, 2022
Randomized trial of three IVIg doses for treating chronic inflammatory demyelinating polyneuropathyDavid R Cornblath, Pieter A van Doorn, Hans-Peter Hartung, et al.Drug Safety|June 28, 2023
Safety and Tolerability of Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy: Results of the ProCID StudyDavid R Cornblath, Pieter A van Doorn, Hans-Peter Hartung, et al.Critical Care Medicine|January 5, 2010
A framework for diagnosing and classifying intensive care unit-acquired weaknessRobert D Stevens, Scott A Marshall, David R Cornblath, et al.Clinical Drug Investigation|July 17, 2023
Peripheral Nerve Safety of Nerve Growth Factor Inhibition by Tanezumab: Pooled Analyses of Phase III Clinical Studies in Over 5000 Patients with OsteoarthritisMark T Brown, David R Cornblath, Martin Koltzenburg, et al.Pageof 8